

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Allen Charles W</u> _____ (Last) (First) (Middle) C/O 60 DEGREES PHARMACEUTICALS, INC. 1025 CONNECTICUT AVENUE NW SUITE 1000 _____ (Street) WASHINGTON DC 20036 _____ (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> 07/11/2023	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>60 DEGREES PHARMACEUTICALS, INC. [ SXTPT ]</u>	
		<b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10,000	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Non-Qualified Stock Options (right to buy) <sup>(1)</sup>	07/11/2023	07/11/2028	Common Stock	9,434 <sup>(2)</sup>	5.3	D	
Restricted Stock Units	(3)	(3)	Common Stock	8,000 <sup>(3)</sup>	(3)	D	
Non-Qualified Stock Options (right to buy) <sup>(1)</sup>	07/11/2023	07/11/2028	Common Stock	7,548 <sup>(4)</sup>	5.3	D	

**Explanation of Responses:**

- Non-Qualified Stock Option granted pursuant that certain Board of Directors Agreement, dated November 28, 2022, between the Issuer and the Reporting Person, subject to terms and conditions of the Issuer's 2022 Equity Incentive Plan.
- Fully vested as of the date of grant.
- Granted on July 11, 2023 and vests in equal quarterly installments over a period of twelve months.
- Vests in equal monthly installments over a period of twelve months.

/s/ Charles Allen

07/11/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.